Inactivation of Gi proteins induces an antidepressant-like effect in the mouse forced-swimming test. by Galeotti, Nicoletta et al.
Neuropharmacology 43 (2002) 457–465
www.elsevier.com/locate/neuropharm
Inactivation of Gi proteins induces an antidepressant-like effect in
the mouse forced-swimming test
Nicoletta Galeotti, Alessandro Bartolini, Carla Ghelardini ∗
Department of Preclinical and Clinical Pharmacology, Univeristy of Florence, Viale G. Pieraccini 6, I-50139 Florence, Italy
Received 17 October 2001; received in revised form 22 May 2002; accepted 6 June 2002
Abstract
The effect of Gi protein inactivation was evaluated in an animal model of depression, the mouse forced swimming test. Animals
were i.c.v. injected with pertussis toxin (PTX) or with antisense oligodeoxynucleotides directed against the α subunit of each Gi-
protein subtype (anti-Giα1, anti-Giα2, anti-Giα3, anti-Goα1, anti-Goα2). The administration of PTX (0.25 µg per mouse i.c.v.)
produced an increase in the mobility time. Similarly, anti-Giα2 (25 µg per mouse i.c.v.), anti-Giα3 (25 µg per mouse i.c.v.), anti-
Goα1 (12.5–25 µg per mouse i.c.v.) and anti-Goα2 (12.5–25 µg per mouse i.c.v.) increased the mobility time. The antidepressant-
like effect obtained was similar to that produced by amitriptyline and clomipramine. By contrast, pretreatment with anti-Giα1 (3.12–
25 µg per mouse i.c.v.) never modified the mobility time in comparison with control animals. At the highest effective doses, none
of the compounds used impaired motor coordination (rota rod test), nor modified spontaneous motility and inspection activity, (hole
board test). These results indicate the involvement of Gi2, Gi3, Go1, and Go2, but not Gi1, protein subtypes in the transduction
mechanism responsible for the induction of an antidepressant-like effect in the mouse forced swimming test.  2002 Elsevier
Science Ltd. All rights reserved.
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1. Introduction
Biochemical research in affective disorders has
focused on the cascade of events involved in signal
transduction: from the level of primary messenger to the
level of neurotransmitter receptor, and, lately, to infor-
mation transduction mechanisms beyond the receptors,
involving G-proteins. Interest in G-proteins comes from
the fact that abnormalities in their function and
expression have been associated with various human dis-
eases and pathophysiological states (Spiegel, 1995). G-
proteins are a ubiquitous family of proteins that play a
crucial role in transducing extracellular signals to cellu-
lar targets, thus transmitting messages from cell surface
receptors to cellular effectors including adenylate
cyclase, phospholipase C and ion channels (Sprang,
1997). G-proteins are heterotrimeric molecules com-
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posed of three different subunits termed α, β and γ. The
α subunits can be classified into families, depending on
whether they are targets for cholera toxin (Gs), pertussis
toxin (Gi and Go) or neither (Gq and G12) (Simon et
al., 1991).
There is now increasing evidence for the involvement
of G-proteins in the pathophysiology of a number of psy-
chiatric diseases such as major depression and bipolar
disorders, and in the biochemical mechanisms underly-
ing the treatment of these disorders (Manji, 1992; Hud-
son et al., 1993). Abnormalities in the signal-transducing
G-proteins have been demonstrated by several studies.
Hyperfunctional Gs proteins were detected in mono-
nuclear leukocytes of patients with mania (Schreiber et
al., 1991) and in cerebral cortex of patients with bipolar
disorders (Young et al., 1993). High Gsα immunoreac-
tivity was found in post-mortem cerebral cortex, mono-
nuclear leukocytes, platelets of patients with bipolar dis-
orders (Young et al., 1991, 1994; Mitchell et al., 1997).
Furthermore, increased levels of Gsα mRNA were
observed in granulocytes from patients with bipolar dis-
orders (Spleiss et al., 1998) even if no alteration was
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detected in cerebral cortex of post-mortem brain from
subjects with ante-mortem diagnosis of bipolar disorder
(Young et al., 1996a).
Contrary to Gs-proteins, the role of Gi-proteins in the
pathogenesis of depressive disorders is more contro-
versial. Higher levels of Giα were found in leukocytes
and platelets from bipolar and major depressed patients
(Young et al., 1994; Garcia-Sevilla et al., 1997). Con-
versely, lower levels of Giα were found in leukocytes
and post-mortem brain of patients with major depression
(Pacheco et al., 1996; Avissar et al., 1997). No signifi-
cant change in Giα levels was observed in mononuclear
leukocytes from patients with major depressive disorder
(Young et al., 1994) or bipolar disorders (Manji et al.,
1995). Furthermore, chronic treatment with antidepress-
ant drugs has been reported to produce either a reduction
or an increase of Giα and Goα protein and mRNA levels
in various regions of rat brain (Lesch et al., 1991; Raap
et al., 1999) and in depressed patients (Avissar et al.,
1997; Karege et al., 1998). By contrast, no alteration in
Giα and Goα protein and mRNA levels was observed
after chronic treatment with tricyclic antidepressants and
monoamine oxidase inhibitors in rat brain (Chen and
Rasenick, 1995; Emamghoreishi et al., 1996; Dwivedi
and Pandey, 1997) and in mononuclear leukocytes from
depressed subjects (Young et al., 1996b).
In light of these controversial data, the aim of the
present study was to further elucidate the role of the Gi-
protein family in the induction of a depressant-like con-
dition by using the mouse forced swimming test, an ani-
mal model of depression. In particular, we injected mice
with antisense oligonucleotides (aODN) against the α
subunits of the Gi1, Gi2, Gi3, Go1 and Go2 proteins in
order to determine the role of each subtype in a depress-
ant-like condition. In order to exclude that the effects
produced by aODN treatments were due to the induction
of side effects, some additional behavioural tests (rota
rod, hole board) were performed.
2. Methods
2.1. Animals
Male Swiss albino mice (23–25 g) from the Morini
(San Polo d’Enza, Italy) breeding farm were used. Fif-
teen mice were housed per cage (26×41 cm). The cages
were placed in the experimental room 24 h before the
test for acclimatisation. The animals were fed a standard
laboratory diet and tap water ad libitum and kept at
23±1°C with a 12 h light/dark cycle, light on at 7 a.m.
All experiments were carried out in accordance with the
European Communities Council Directive of 24 Nov-
ember 1986 (86/609/EEC) for experimental animal care.
All efforts were made to minimise animal suffering, and
to reduce the number of animals used.
2.2. Intracerebroventricular injection technique
Intracerebroventricular (i.c.v.) administration was per-
formed under ether anaesthesia, according to the method
described by Haley and McCormick (1957). Briefly, dur-
ing anaesthesia, mice were grasped firmly by the loose
skin behind the head. A 0.4 mm external diameter hypo-
dermic needle attached to a 10 µl syringe was inserted
perpendicularly through the skull and no more than 2
mm into the brain of the mouse, where 5 µl were then
administered. The injection site was 1 mm to the right
or left from the midpoint on a line drawn through to the
anterior base of the ears. Injections were performed into
the right or left ventricle randomly. To ascertain that the
drugs were administered exactly into the cerebral ven-
tricle, some mice (20%) were injected with 5 µl of
diluted 1:10 India ink and their brains examined macro-
scopically after sectioning. The accuracy of the injection
technique was evaluated and the percentage of correct
injections was 95.
2.3. Forced swimming test
The forced swimming test used was the same as
described by Porsolt et al. (1977). Briefly, mice were
dropped individually into glass cylinders (height: 25 cm,
diameter: 10 cm) containing 6 cm of water maintained
at 22–23°C and left there for 6 min. A mouse was judged
to be immobile when it floated in the water, in an upright
position, and made only small movements to keep its
head above water. The duration of mobility was recorded
during the last 4 min of the 6-min test. An increase in
the duration of mobility is indicative of an antidepress-
ant-like effect. The test was performed 24–18 h after
i.c.v. injections of ODNs, 4–11 days after PTX adminis-
tration, 30 min after tricyclic antidepressants injection.
2.4. Hole-board test
The hole board test consisted of a 40 cm square plane
with 16 flush mounted cylindrical holes (3 cm diameter)
distributed 4 by 4 in an equidistant, grid-like manner.
Mice were placed on the centre of the board one by one
and allowed to move about freely for a period of 10 min
each. Two electric eyes, crossing the plane from mid-
point to mid-point of opposite sides, thus dividing the
plane into 4 equal quadrants, automatically signalled the
movement of the animal (counts in 5 min) on the surface
of the plane (locomotor activity). Miniature photoelectric
cells, in each of the 16 holes, recorded (counts in 5 min)
the exploration of the holes (exploratory activity) by the
mice. The test was performed 24–18 h after the i.c.v.
injections of degenerate ODN (dODN; 12.5 µg per
mouse) or aODN (6.25–12.5 µg per mouse), 11 days
after administration of PTX. 12–15 mice per group
were tested.
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2.5. Rota-rod test
The apparatus consisted of a base platform and a rotat-
ing rod with a diameter of 3 cm and a non-slippery sur-
face. The rod was placed at a height of 15 cm from the
base. The rod, 30 cm in length, was divided into 5 equal
sections by 6 disks. Thus, up to 5 mice were tested sim-
ultaneously on the apparatus, with a rod-rotating speed
of 16 r.p.m. The integrity of motor coordination was
assessed on the basis of the number of falls from the rod
in 30 s according to Vaught et al. (1985). Those mice
scoring less than 3 and more than 6 falls in the pretest
were rejected (20%). The performance time was meas-
ured before (pretest) and 15, 30 and 45 min after s.c.
treatment. Animals were i.c.v. pretreated 24–18 h prior
to the test with degenerate ODN (dODN) or aODN or
11 days before the test with PTX. 12–15 mice per group
were tested.
2.6. Antisense oligonucleotides
The sequences of the antisense oligonucleotides
(ODNs) used in the present study are shown in Table 1.
Phosphodiester ODNs protected from terminal phos-
phorothioate double substitution (capped ODNs) against
possible exonuclease-mediated degradation were used
(Tib Molbiol, Genova, Italy). All ODNs were previously
characterised by in vitro (immunoblotting) and in vivo
(tail flick) experiments (Kleuss et al., 1991; Raffa et al.,
1994; Sanchez-Blazquez et al., 1995; Sanchez-Blazquez
and Garzon, 1998). A 33-mer fully degenerated ODN
(dODN) 5-N∗N∗N NNN NNN NNN NNN NNN NNN
NNN NNN NNN N∗N∗N -3 (where N is G, or C, or
A, or T) and a 25-mer fully degenerated ODN (dODN)
5-N∗N∗N NNN NNN NNN NNN NNN NNN NN∗N
∗N -3 (where N is G, or C, or A, or T) were used as
a control respectively for anti-Giα and anti-Goα. ODNs
were vehiculated intracellularly by an artificial cationic
lipid (DOTAP, Sigma) to enhance both uptake and stab-
ility, as described previously (Capaccioli et al., 1993).
aODN or dODN were preincubated at 37°C for 30 min
with 13 µM DOTAP and supplied to mice by i.c.v. injec-
tion of 5 µl solution 18 and 24 h prior to the behav-
ioural tests.
Table 1
Sequences of the antisense oligonucleotides
aODN sequences
anti-Giα1 5- G∗C∗T GTC CTT CCA CAG TCT CTT TAT GAC GCC G∗G∗C -3
anti-Giα2 5- A∗T∗G GTC AGC CCA GAG CCT CCG GAT GAC GCC C∗G∗A -3
anti-Giα3 5- G∗C∗C ATC TCG CCA TAA ACG TTT AAT CAC GCC T∗G∗C -3
anti-Goα1 5- A∗G∗G CAG CTG CAT CTT CAT AGG TG∗T ∗T -3
anti-Goα2 5- G∗A∗G CCA CAG CTT CTG TGA AGG CA∗C ∗T -3
2.7. Drugs
The following drugs were used: pertussis toxin (RBI);
clomipramine hydrochloride amitriptyline hydrochlor-
ide, DOTAP (Sigma); D-amphetamine hydrochloride
(De Angeli). All drugs were dissolved in isotonic (NaCl
0.9%) saline solution immediately before use, except for
pertussis toxin which was dissolved in a water solution
containing 0.01 M sodium phosphate buffer, pH=7.0,
with 0.05 M sodium chloride. Drug concentrations were
prepared in such a way that the necessary dose could be
administered in a volume of 10 ml kg1 by s.c. injection
or 5 µl per mouse by i.c.v. injection.
All animals received an i.c.v. injection of dODN or
aODN 18 and 24 h prior to the test; 30 min before the
test mice received a s.c. injection: the group pretreated
with dODN received saline (control group), amitripty-
line, or clomipramine whereas the group pretreated with
aODN received saline.
2.8. Statistical analysis
All experimental results are given as the mean±S.E.M.
analysis of variance (ANOVA), followed by Fisher’s
Protected Least Significant Difference (PLSD) procedure
for post-hoc comparison, was used to verify significance
between two means. Data were analysed with the Stat-
View software for the Macintosh (1992). P values of
less than 0.05 were considered significant.
3. Results
3.1. Effect of pertussis toxin
Pretreatment with pertussis toxin (PTX) produced an
antidepressant-like effect in the mouse forced swimming
test. PTX, injected i.c.v. at the dose of 0.25 µg per mouse
11 days before the test, increased the mobility time,
whereas 4 days after injection was devoid of any effect
(Fig. 1). The vehicle used to dissolve PTX did not mod-
ify the animals’ mobility time in comparison with
untreated (naive) or saline-treated groups (Fig. 1).
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Fig. 1. Increase by pertussis toxin (PTX) of the mobility time in the mouse forced swimming test. The test was performed before, 4 and 11 days
after a single i.c.v. injection of saline, vehicle or PTX (0.25 µg per mouse). Vertical lines represent s.e.m.; between 12 and 15 mice were tested.
∗∗P0.01 in comparison with vehicle-treated mice.
3.2. Effect of aODN against Gia and Goa subunits
The administration of an aODN against the α subunit
of the Gi2 proteins (25 µg per mouse i.c.v.) increased
the mobility time in the mouse forced swimming test up
to a value comparable to that produced by amitriptyline
(15 mg kg1 s.c.) and clomipramine (25 mg kg1 s.c.),
used as reference drugs. Lower doses were ineffective
(Fig. 2). Anti-Giα3 at 3.12 µg per mouse i.c.v. was
devoid of any effect. At 6.25 and 12.5 µg per mouse
i.c.v., the mobility time was slightly increased, even if
the statistical significance was not reached. The doses of
25 µg per mouse i.c.v. showed a significant antidepress-
ant-like effect (Fig. 2). Anti-Giα1 (3.12–25 µg per mouse
i.c.v.), contrary to anti-Giα2 and anti-Giα3, was unable
to modify the mobility time at all doses tested (Fig. 2).
Anti-Goα1 (1.56–25 µg per mouse i.c.v.) produced a
dose-dependent increase of the mobility time of mice.
The doses of 1.56 and 3.12 µg per mouse i.c.v. were
ineffective, the dose of 6.25 increased the mobility time
even if the statistical significance was not reached. At
12.5 µg per mouse a significant antidepressant-like effect
was produced. The highest effect of anti-Goα1 was
reached at the doses of 25 µg per mouse i.c.v. (Fig. 3).
The administration of an aODN against the α subunit of
the Go2 proteins (1.56–25 µg per mouse i.c.v.), similarly
to anti-Goα1, increased the mobility time in a dose-
dependent manner reaching the highest effect at 25 µg
per mouse i.c.v. (Fig. 3). The anti-depressant like effect
produced by anti-Go treatment was comparable to that
exerted by amitriptyline (15 mg kg1 s.c.) and clomipra-
mine (25 mg kg1 s.c.), used as reference drugs (Fig. 3).
The antidepressant-like effect produced by aODNs, at
the highest doses tested, disappeared 7 days after the end
of treatment. The mobility time recorded in each group
was comparable to that of dODN-treated mice (Fig. 4).
3.3. Effect of PTX and aODN against Gia and Goa
subunits on mouse behaviour
It should be noted that PTX and the aODNs under
investigation elicited their modulatory effects on
mobility time in the forced swimming test without alter-
ing motor coordination, as revealed by the rota rod test
(Fig. 5). In this test, each group progressively reduced
its number of falls because mice learned how to balance
on the rotating rod. PTX (0.25 µg per mouse i.c.v.) did
not modify the number of falls from the rotating rod
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Fig. 2. Effect of pretreatment with an antisense oligonucleotide (aODN) to the α subunit of Gi1 (3.12–25 µg per mouse i.c.v.), Gi2 (3.12–25 µg
per mouse i.c.v.), Gi3 (3.12–25 µg per mouse i.c.v.) protein gene in the mouse forced swimming test. The test was performed 18–24 h after the
i.c.v. injections of degenerate ODN (dODN; 12.5 µg per mouse i.c.v.) or aODN. Amitriptyline (AMI, 15 mg kg1 s.c.) and clomipramine (CLO,
25 mg kg1 s.c.) were administered 30 min before the test. Vertical lines represent s.e.m.; between 16 and 23 mice were tested. ∗P0.05, ∗∗P0.01
in comparison with dODN.
in comparison with untreated (naive), saline- or vehicle-
treated mice (Fig. 5(A)). The motor coordination of mice
pretreated with aODN to Giα1 (25 µg per mouse i.c.v.),
Giα2 (25 µg per mouse i.c.v.), Giα3 (25 µg per mouse
i.c.v.), Goα1 (25 µg per mouse i.c.v.), and Goα2 (25 µg
per mouse i.c.v.) was unaltered in the rota rod test. The
number of falls of aODN-treated groups was comparable
to that of the dODN-treated mice (Fig. 5(B)B).
The spontaneous motility and exploratory activity of
mice was not modified by administration of PTX (0.25
µg per mouse i.c.v.), and the above-mentioned aODNs
(25 µg per mouse i.c.v.) as revealed by the hole-board
test in comparison with untreated (naive), saline-, and
dODN (25 µg per mouse i.c.v.)-treated mice (Fig. 6). In
the same experimental conditions D-amphetamine (2 mg
kg1 s.c.), used as the reference drug, increased both
parameters evaluated.
4. Discussion
Signal transduction mechanisms mediated by Gi pro-
teins appear to be involved in the modulation of depress-
ive states as evidenced by results from the forced swim-
ming test in mice. Inactivation as well as inhibition of
expression of Gi proteins provoke an increase of mouse
mobility time inducing an antidepressant-like effect of
an intensity comparable to that produced by the tricyclic
antidepressants amitriptyline and clomipramine, used as
reference drugs.
The forced swimming test is widely used to predict
the antidepressant action of drugs in humans. The
mobility time of mice in this test is increased by the
majority of antidepressants including tricyclic and atypi-
cal antidepressants, MAO inhibitors and 5-HT uptake
inhibitors (Porsolt et al., 1977; Bourin et al., 1991), and
their effectiveness correlates significantly with clinical
potency (Willner, 1984). However, this animal model
has also some drawbacks represented by the possibility
of obtaining some false positives or negatives (Borsini
and Meli, 1988; Detke and Lucki, 1996). Drugs enhanc-
ing motor activity, such as anticholinergics and antihista-
mines, may give a “false” positive effect in the forced
swimming test and antidepressants such as bupropion,
nomifensine and amineptine would then be rejected
since they increase motor activity (Borsini and Meli,
1988).
Present results indicate that the inactivation of Gi pro-
teins is required for the induction of an antidepressant-
like effect in the mouse forced swimming test. The
administration of pertussis toxin (PTX), a bacterial toxin
produced by Bordetella pertussis that ADP-ribosylates
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Fig. 3. Effect of pretreatment with an antisense oligonucleotide (aODN) to the α subunit of Go1 (1.56–25 µg per mouse i.c.v.) and Go2 (1.56–
25 µg per mouse i.c.v.) protein gene in the mouse forced swimming test. The test was performed 18–24 h after the i.c.v. injections of degenerate
ODN (dODN; 12.5 µg per mouse i.c.v.) or aODN. Amitriptyline (15 mg kg1 s.c.) and clomipramine (25 mg kg1 s.c.) were injected 30 min
before the test. Vertical lines represent s.e.m.; between 18 and 21 mice were tested. ∗P0.05, ∗∗P0.01 in comparison with dODN.
Fig. 4. Lack of effect by pretreatment with an aODN to the α subunit
of Gi1 (25 µg per mouse i.c.v.), Gi2 (25 µg per mouse i.c.v.), Gi3 (25
µg per mouse i.c.v.), Go1 (25 µg per mouse i.c.v.), and Go2 (25 µg
per mouse i.c.v.) protein gene in the mouse forced swimming test 7
days after the i.c.v. injection of dODN (25 µg per mouse i.c.v.) or
aODNs. Vertical lines represent s.e.m.; 15 mice per group were tested.
and inactivates the α subunit of Gi-protein family
(Katada and Ui, 1982), enhanced the mobility time of
mice and, therefore, counteracted the depressant-like
condition induced in the test. These data evidence the
important role played by Gi proteins in the signal trans-
duction mechanism responsible for the modulation of
depressive states. The Gi protein subfamily is composed
by different members, Gi1, Gi2, Gi3, Go1, and Go2
(Simon et al., 1991). Since PTX inactivates all members
of the Gi-protein family, the role of each subtype was
investigated by pretreating animals with aODNs against
the α subunits of the above-mentioned Gi and Go protein
subtypes. The inhibition of the expression of Giα2, Giα3,
Goα1, and Goα2 produced a dose-dependent increase of
mobility time, whereas the administration of an aODN
against Giα1 never exerted any effect in comparison with
control animals. These results indicate a differential
involvement of the Gi protein subtypes in the modulation
of depressive states in mice. In particular, the inhibition
of the expression of Gi2, Gi3, Go1, and Go2 proteins
appears essential to produce an antidepressant-like
effect. In particular, Go1 and Go2 subtypes appear to be
endowed with a prominent role since the anti-Go1 and
anti-Go2 increased the mobility time at lower doses than
anti-Gi2 and anti-Gi3. The observation that chronic treat-
ment with the antidepressant drug imipramine decreases
Goα mRNA levels in the rat hippocampus without mod-
ifying Giα mRNA levels (Lason and Przewlocki, 1993)
further support this hypothesis. Contrary to Gi2 and Gi3,
the Gi1 subtype appears not to be involved in the modu-
lation of mobility time implying that this subunit is not
a major component in the transduction mechanisms
involved in the induction of a depressive condition.
From these data we can hypothesise that activation of
the transduction system mediated by Gi proteins may
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Fig. 5. Effect of PTX (panel A) and aODN (panel B) to the α subunit
of Gi1 (25 µg per mouse i.c.v.), Gi2 (25 µg per mouse i.c.v.), Gi3 (25
µg per mouse i.c.v.), Go1 (25 µg per mouse i.c.v.), Go2 (25 µg per
mouse i.c.v.) protein gene on motor coordination in the mouse rota
rod test. The test was performed 24–18 h after the i.c.v. injection of
dODN (25 µg per mouse i.c.v.) or aODN. Vertical lines represent
s.e.m.
result in the induction of a depressive state. Neverthe-
less, studies on the quantification of Gi protein levels in
depressed patients are controversial (see introduction).
These discrepancies may stem from the severity of ill-
ness in the patients included in each study and from the
heterogeneity of biological sample used (post-mortem
brain, peripheral blood cells etc.). However, a change
in the protein or mRNA amount does not always imply
defective protein function, but rather often appears to
reflect compensatory consequences. As a matter of fact,
even if no clear alteration at protein or mRNA Gi protein
level emerged, an hyperfunctionality of this transduction
mechanism has been evidenced. Gi-proteins represent
the most widespread modulatory signalling pathway in
neurones (Holtz et al., 1986) and one of their principal
effects is the inhibition of adenylate cyclase activity
(Sprang, 1997). A significant elevation in hydrolysis-
resistant photoaffinity GTP analog (AAGTP) binding to
Gi/o and a decrease in the ratio Gs/Gi AAGTP incorpor-
ation was seen in parietal and temporal cortices of uni-
polar depressive patients (Ozawa et al., 1993). It has also
been reported that basal and stimulated adenylate cyclase
activity, as well as cAMP response element binding pro-
tein (CREB) levels, were reduced in post-mortem brain
of subjects with mood disorders (Cowburn et al., 1994;
Young et al., 1996b; Dowlatshahi et al., 1999). More-
over, in response to antidepressant treatment, increased
cAMP activity (Perez et al., 1991) and enhanced
expression and activity of CREB (Nibuya et al., 1996;
Thome et al., 2000) has been demonstrated in rat brain.
Since adenylate cyclase is regulated by the balance
between Gs and Gi functions, an imbalance in this mess-
enger system evidenced by these data further suggests
that depression may be a state occurring during hypo-
function of the adenylate cyclase pathway.
Pretreatment with dODN, used as the reference ODN,
never modified the increase of mobility time in the
mouse forced swimming test in comparison with
untreated (naive) or saline-treated animals, excluding the
possibility of a sequence-independent effect induced by
the aODNs. Moreover, the antidepressant-like effect
induced by anti-Giα and anti-Goα disappeared 7 days
after administration, indicating an absence of irreversible
damage or toxicity on cerebral structures caused by
the aODNs.
Numerous hormones and neurotransmitters activate
the Gi-protein system. The administration of PTX and
aODN against the α subunits of Gi proteins could induce
side effects that make the interpretation of the results
obtained difficult. Furthermore, since drugs that modify
motor activity may give false positive or negative
effects, it is suitable to carry out a test to check this
aspect, in parallel with forced swimming test. The high-
est doses of the drugs used in the present work were
devoid of behavioural side effects. PTX and ODNs were
tested on the rota-rod test before the forced swimming
test was performed, to make sure that they did not influ-
ence the normal motor coordination of the mice. Since
ataxic mice are not able to coordinate movements and
fall from the rotating rod, while excited animals tend to
jump off the rod, the good performance on the rod by
mice in the present study indicates the results obtained
with the forced swimming test are not due to altered
motor activity induced by substances at the doses used.
Furthermore, not only altered motor coordination but
also a modified spontaneous motility could lead to a mis-
interpretation of the results obtained in the forced swim-
ming test. An influence of the substances used on spon-
taneous motility has, therefore, been excluded by using
the hole board test. Moreover, drugs which have a
known psychostimulant effect, like (+)-amphetamine
and caffeine, at the same doses at which they are able
to increase the time of mobility in the rat forced swim-
ming test, also show a significant increased motor
activity in an open field (Porsolt et al., 1978).
In conclusion, our results evidence that knockdown of
Giα2, Giα3, Goα1 and Goα2, but not Giα1 induces an
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Fig. 6. Lack of effect of pretreatment with an antisense oligonucleotide (aODN) to the α subunit of Gi1 (25 µg per mouse i.c.v.), Gi2 (25 µg per
mouse i.c.v.), Gi3 (25 µg per mouse i.c.v.), Go1 (25 µg per mouse i.c.v.), Go2 (25 µg per mouse i.c.v.) protein gene on spontaneous motility and
inspection activity in the mouse hole board test. The test was performed 18–24 h after the i.c.v. injections of degenerate ODN (dODN; 25 µg per
mouse) or aODN. Vertical lines represent s.e.m. D-amphetamine was administered at the dose of 1 mg kg1 s.c. ∗P0.05 in comparison with
naive group.
anti-immobility effect comparable to that produced by
the antidepressants in the mouse forced swimming test,
indicating the involvement of this transduction system
in the induction of a depressive-like condition.
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